Robert Schickel, PhD profile page

Dr. Robert Schickel is the chief executive officer and cofounder of NUAgo Therapeutics, a biotechnology company developing small RNA-based therapies targeting critical survival gene networks in cancer. With more than 15 years of experience across biotechnology and pharmaceuticals, he has led strategy, business development, and scientific innovation focused on advancing novel therapeutics and therapeutic platforms. Schickel holds a BSc in chemistry/biochemistry from the University of California, San Diego, and a PhD in biomedical sciences from the University of Chicago. He combines expertise in translational oncology, company building, and scientific and commercial risk mitigation across multiple stages of development. Prior to founding NUAgo Therapeutics, he advised senior executives of life science companies on corporate strategy, portfolio prioritization, and asset evaluation across a range of therapeutic areas and market opportunities.